Correspondence 0001437749-23-003138 from Panbela Therapeutics, Inc. (PBLA) (CIK 0001029125)
Panbela Therapeutics, Inc. (PBLA) (CIK 0001029125)
Date: Feb. 13, 2023 · CIK: 0001029125 · Accession: 0001437749-23-003138
AI Filing Summary & Sentiment
File numbers found in text: 333-269711
Letter
pbla20230211_corresp.htm
February 13, 2023
VIA EDGAR TRANSMISSION
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-6010
Attn: Alan Campbell
Re:
Panbela Therapeutics, Inc.
Registration Statement on Form S-1 (Registration No. 333-269711)
Request for Acceleration of Effective Date
Ladies and gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Panbela Therapeutics, Inc. (the “Company”) hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-269711) (the “Registration Statement”) to become effective on February 14, 2023, at 4:30 p.m., Eastern Time, or as soon as thereafter possible. The Company hereby acknowledges its responsibilities under the Act as they relate to the proposes public offering of the securities specified in the Registration Statement.
Please direct any questions or comments concerning this request to Joshua L. Colburn of Faegre Drinker Biddle & Reath LLP, counsel to the Company, at +1 (612) 766-8946.
[Signature Page Follows]
Very truly yours,
PANBELA THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm pbla20230211_corresp.htm February 13, 2023 VIA EDGAR TRANSMISSION Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-6010 Attn: Alan Campbell Re: Panbela Therapeutics, Inc. Registration Statement on Form S-1 (Registration No. 333-269711) Request for Acceleration of Effective Date Ladies and gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Panbela Therapeutics, Inc. (the “Company”) hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-269711) (the “Registration Statement”) to become effective on February 14, 2023, at 4:30 p.m., Eastern Time, or as soon as thereafter possible. The Company hereby acknowledges its responsibilities under the Act as they relate to the proposes public offering of the securities specified in the Registration Statement. Please direct any questions or comments concerning this request to Joshua L. Colburn of Faegre Drinker Biddle & Reath LLP, counsel to the Company, at +1 (612) 766-8946. [Signature Page Follows] Very truly yours, PANBELA THERAPEUTICS, INC. By: /s/ Susan Horvath Name: Susan Horvath Title: Vice President of Finance, Chief Financial Officer, Treasurer and Secretary